Please login to the form below

abiraterone

This page shows the latest abiraterone news and features for those working in and with pharma, biotech and healthcare.

MSD and AstraZeneca announce phase 3 results for prostate cancer therapy

MSD – known as Merck &Co in the US and Canada – and AstraZeneca have shared positive results from the PROpel phase 3 trial for the combination therapy of Lynparza (olaparib) plus abiraterone ... The data published in NEJM Evidence emphasises the

Latest news

Cancer Research UK drives innovation with Cancer Research Horizons

discovery and development, which includes abiraterone and rucaparib.
Lynparza significantly delays disease progression as first-line treatment in prostate cancer

Now, high-level results from the PROpel phase 3 trial in first-line metastatic castration-resistant prostate cancer (mCRPC) show that Lynparza in combination with abiraterone significantly delayed disease progression. ... The data monitoring committee
CHMP recommends eight new medicines for EU approval

Two generic medicines also received positive opinions from the CHMP: Abiraterone Mylan (abiraterone acetate), a generic of Janssen’s Zytiga, for the treatment of metastatic prostate cancer and Fingolimod Mylan (fingolimod),
Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer

Specifically, Janssen will not pursue regulatory approval based on the phase 3 ACIS study, which evaluated Erleada (apalutamide) and Zytiga (abiraterone acetate) plus prednisone in patients with chemotherapy-naive metastatic
Janssen’s Erleada improves survival in certain advanced prostate cancer patients

Androgen inhibitor Erleada (apalutamide) is Janssen’s follow-up to its older, blockbuster prostate cancer drug Zytiga (abiraterone acetate), which has now been hit by the loss of patent protection and

More from news
Approximately 6 fully matching, plus 65 partially matching documents found.

Latest Intelligence

Deal Watch May 2016

outperforming J&J's Zytiga [abiraterone].
Taking a strategic approach

But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen
Pharma deals during October 2013

AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy
Interview: Cesar Rodriguez, Janssen

Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “a